Rakovina Therapeutics Inc. shares have taken a significant hit, dropping over 11% in a single trading day.
In the latest trading session, Rakovina Therapeutics Inc (RKV.V) experienced a sharp decline, closing at CA$0.12, down 11.54%. This downturn raises concerns for investors as the company continues to face financial challenges without any recent positive news to bolster investor confidence.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Rakovina Therapeutics Inc
RKV.V
RKV.V
Rakovina Therapeutics Inc
WealthAwesomeMarket cap
$3.17M
52W high
$0.75
52W low
$0.09
1W change
+0.00%
Beta
-0.21
Analyst Price Targets
Based on analyst covering RKV
Wall Street analysts forecast RKV stock price to rise 2976.9% over the next 12 months.
Consensus
No RatingAvg. Target
C$4.00
+2976.9% Upside
Current Price
C$0.13
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RKV's historical volatility
30-Day Vol
79.2%
Annualized
90-Day Vol
145.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.16
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.14 | C$0.10 โ C$0.18 |
| 60 trading days | C$0.15 | C$0.10 โ C$0.22 |
| 90 trading days | C$0.16 | C$0.10 โ C$0.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious as Rakovina's recent performance reflects ongoing financial struggles, and the lack of positive developments could further impact stock sentiment.
Rakovina's stock tumbles 11.54% in one day.
The market cap now stands at approximately CA$3.17 million, reflecting investor skepticism amidst ongoing losses.
Bull case
If Rakovina can successfully navigate its financial hurdles and leverage its research advancements, there could be potential for recovery in the long term. Investors might see a turnaround if the company can stabilize its finances and deliver promising results from its research initiatives.
Bear case
On the flip side, continued financial losses and a lack of significant news could lead to further declines, making this a risky investment for the foreseeable future. Without any positive developments, investor confidence may continue to erode, impacting the stock's performance.
Recent Performance Overview
Rakovina Therapeutics Inc. has faced a challenging trading day, with shares plummeting by 11.54%. This decline is particularly concerning given the company's current market cap of CA$3.17 million and its ongoing financial losses, including a reported net loss of over $2 million in Q1 2025. Investors are left wondering about the future viability of the company, especially in light of the absence of any recent positive news or developments.
Financial Challenges Ahead
The company's financial reports reveal significant losses, including R&D and G&A expenses that continue to mount. With no recent announcements to counterbalance these losses, investor confidence is waning. The recent share consolidation may also have contributed to the negative sentiment, as it often signals underlying issues within a company. Investors should remain vigilant and consider the risks associated with holding RKV.V shares at this time.
Advertisement
